Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC
Primary objective of this study is to evaluate the efficacy of gemcitabine and cisplatin as first line therapy in patients with triple-negative MBC. 80 patients will be treated into this study.
Metastatic Breast Cancer
DRUG: gemcitabine and cisplatin
PFS (progression free survival), 1 year
side effects, 6 months|BRCA1 mutation realtionship with efficacy and toxicity analysis, at the end of therapy|pharmacogenetic analysis, collect blood samples before therapy
Triple-negative breast tumors could contribute to the poor prognosis comparing with luminal A breast cancer.Fewer study has revealed that Cisplatin-based therapy may be effective for this type breast cancer.